Ikametin

Ibandronic Acid, the active ingredient in Ikametin, is a bisphosphonate presented as an oral tablet for systemic use. It is employed to treat bone‑loss conditions such as osteoporosis and Paget’s disease in adult patients.

GNH USA supplies Ikametin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through regulated channels.

Ikametin (ibandronic acid) acts on bone metabolism by inhibiting osteoclast‑mediated resorption, and is indicated for:

Postmenopausal osteoporosis: reduces the risk of vertebral fractures in women after menopause. Glucocorticoid‑induced osteoporosis: helps maintain bone density in patients receiving long‑term corticosteroid therapy. Paget’s disease of bone: normalises elevated bone turnover associated with the disorder.

Ibandronic acid may cause a range of adverse reactions. Most are mild and reversible, but rare serious events have been reported.

Common Side Effects: - Upper gastrointestinal irritation or dyspepsia - Nausea or abdominal pain - Musculoskeletal pain, especially in the back or joints - Headache - Transient flu‑like symptoms after the first dose - Diarrhoea or constipation

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ) - Atypical femur fracture - Severe acute phase reaction with fever and severe bone pain - Acute renal impairment or worsening of pre‑existing kidney disease - Hypersensitivity reactions including rash or anaphylaxis - Severe musculoskeletal pain persisting beyond 48 hours

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

Assess renal function: avoid use in patients with severe renal impairment. Correct calcium and vitamin D status: ensure adequate supplementation before treatment. Avoid concomitant calcium, antacids or iron within 30 minutes of the dose to prevent reduced absorption. Take with a full glass of water and remain upright for at least 30 minutes to minimise esophageal irritation. Contraindicated in hypocalcaemia: correct serum calcium before starting. Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Ibandronic acid can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent use of other bisphosphonates or potent anti‑resorptive agents. - Co‑administration with nephrotoxic drugs (e.g., aminoglycosides, amphotericin B) that may exacerbate renal risk. - Simultaneous intake of calcium, magnesium, aluminium or iron supplements within 30 minutes of the dose, which markedly lowers absorption.

Moderate Interactions (Monitor Closely): - NSAIDs or aspirin: may increase gastrointestinal irritation. - Systemic corticosteroids: can augment bone loss, requiring closer monitoring of bone density. - Vitamin D analogues: monitor calcium levels to avoid hypercalcaemia.